Our Company
About us
About Xanamem
®
(emestedastat)
Xanamem® Pipeline
Our Team
Recent Annual Reports
Our Strategic Priorities
Corporate Governance
Xanamem
®
(emestedastat)
Mechanism of Action
The Cortisol Hypothesis
Publications
Clinical Trials
Clinical Development Pipeline
Cognitive Impairment in early Alzheimer’s Disease
Cognitive Impairment in MDD
Patient Portal
The XanaMIA Phase 2b/3 Alzheimer’s Trial
Publications
Investor Centre
News
Contact Us
BACK TO NEWS
admin • 06 Jan 2023
Edison themes: Outlook for 2023
Biotechs remain central to novel drug development
